Search results for "Immunocompromise"

showing 10 items of 98 documents

Reconstruction of critical-size mandibular defects in immunoincompetent rats with human adipose-derived stromal cells

2013

In patients with bony defects, autologous bone grafts are the "gold standard" for reconstruction. In children, autologous bone harvesting is limited but tissue engineering offers an alternative. Next to bone marrow, adipose tissue is a source of mesenchymal stromal cells, and adipose-derived stromal cells (ADSC) can differentiate into osteocytes. The aim of this study was to evaluate the efficacy of bioactive implants (ADSC in fibrin glue) for repair of critical-size mandibular defects in athymic rats. Human adult ADSC embedded in fibrin glue were implanted into a critical-size defect in the rat mandible and their efficacy was compared to those of protected bone healing (pbh), autologous bo…

AdultMalePathologymedicine.medical_specialtyStromal cellAdipose tissueFibrin Tissue AdhesiveBone healingOsteocytesImmunocompromised HostRandom AllocationRats NudeTissue engineeringOsteogenesisImage Processing Computer-AssistedAnimalsHumansMedicineMandibular DiseasesIn patientAutograftsFibrin glueWound HealingBone TransplantationTissue EngineeringTissue Scaffoldsbusiness.industryMesenchymal stem cellMesenchymal Stem CellsX-Ray MicrotomographyAnatomyRatsmedicine.anatomical_structureAdipose TissueOtorhinolaryngologySurgeryBone marrowMandibular ReconstructionOral SurgeryTomography X-Ray ComputedbusinessJournal of Cranio-Maxillofacial Surgery
researchProduct

Zygomycosis in Italy: A survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology)

2009

Abstract The aims of the study were to analyze the clinical and epidemiological characteristics and treatments for patients who developed zygomycosis enrolled in Italy during the European Confederation of Medical Mycology of medical mycology survey. This prospective multicenter study was performed between 2004 and 2007 at 49 italian Departments. 60 cases of zygomycosis were enrolled: the median age was 59.5 years (range 1-87), with a prevalence of males (70%). The majority of cases were immunocompromised patients (42 cases, 70%), mainly hematological malignancies (37). Among non-immunocompromised (18 cases, 30%), the main category was represented by patients with penetrating trauma (7/18, 3…

AdultMalemedicine.medical_specialtyAdolescentEpidemiologyAntifungal drugImmunocompromised HostPharmacotherapyZygomycosisDrug Resistance FungalAmphotericin BInternal medicineEpidemiologymedicineHumansPharmacology (medical)ChildMycosisAgedPharmacologyImmunocompromised hostAged 80 and overbusiness.industryMortality rateMucormycosisInfantEpidemiology; Immunocompromised host; ZygomycosisMiddle Agedmedicine.diseaseSurgeryInfectious DiseasesOncologyItalyChild PreschoolFemaleZygomycosisbusinessmedicine.drug
researchProduct

Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation A Randomized Clinical Trial

2019

###EgeUn###

AdultMalemedicine.medical_specialtyHerpes Zoster Vaccinemedicine.medical_treatmentvirusesVaccines Synthetic/administration & dosageHematopoietic stem cell transplantationPlaceboInjections IntramuscularTransplantation Autologous01 natural sciencesHerpes Zoster Vaccine/administration & dosage03 medical and health sciences0302 clinical medicineAutologous stem-cell transplantationAdjuvants ImmunologicInternal medicinehemic and lymphatic diseasesmedicineHumansSingle-Blind Method030212 general & internal medicine0101 mathematicsAdverse effectHospitalization/statistics & numerical dataProportional Hazards ModelsImmunocompromised hostintegumentary systembusiness.industryIncidence (epidemiology)010102 general mathematicsvirus diseasesGeneral MedicineMiddle AgedNeuralgia Postherpetic/prevention & controlTransplantationsurgical procedures operativeHerpes Zoster/epidemiologyhematopoietic stem cell transplantationoncologyincidenceFemaleZoster vaccinebusinessFollow-Up Studiesmedicine.drug
researchProduct

A unique fatal case of Waterhouse–Friderichsen syndrome caused by Proteus mirabilis in an immunocompetent subject

2019

Abstract Introduction: The Waterhouse–Friderichsen syndrome (WFS), also known as purpura fulminans, is a potentially lethal condition described as acute hemorrhagic necrosis of the adrenal glands. It is often caused by infection. Classically, Neisseriae meningitidis represents the main microorganism related to WFS, although, infrequently, also other infectious agents are reported as a possible etiologic agent. The authors report the first case of death due to Proteus mirabilis infection, with postmortem evidence of WFS. Patient concerns: After a facial trauma that provoked a wound on the nose, the subject, a healthy 40-years old man, was conducted to the local hospital (in Sicily, Italy) af…

AdultMalemedicine.medical_specialtySepsiforensic sciencesAutopsyGastroenterologysepsisSepsisImmunocompromised Host03 medical and health sciences0302 clinical medicineSettore MED/43 - Medicina LegaleInternal medicinemedicineWaterhouse–Friderichsen syndromeHumansClinical Case Report030212 general & internal medicineLeukocytosisProteus mirabilisWaterhouse-Friderichsen syndromeDisseminated intravascular coagulationbiology4900business.industryBilateral massive adrenal hemorrhageWaterhouse-Friderichsen syndrome: XGeneral Medicinemedicine.diseasebiology.organism_classificationProteus InfectionProteus mirabilisBilateral massive adrenal hemorrhage; Forensic sciences; Proteus mirabilis infection; Sepsis; Waterhouse-Friderichsen syndrome; Adult; Humans; Male; Proteus Infections; Waterhouse-Friderichsen Syndrome; Immunocompromised Host; Proteus mirabilisProteus mirabilis infection030220 oncology & carcinogenesisForensic sciencemedicine.symptomProteus InfectionsbusinessAdrenal HemorrhageResearch ArticleHumanPurpura fulminansMedicine
researchProduct

Future challenges and chances in the diagnosis and management of invasive mould infections in cancer patients

2020

Abstract Diagnosis, treatment, and management of invasive mould infections (IMI) are challenged by several risk factors, including local epidemiological characteristics, the emergence of fungal resistance and the innate resistance of emerging pathogens, the use of new immunosuppressants, as well as off-target effects of new oncological drugs. The presence of specific host genetic variants and the patient's immune system status may also influence the establishment of an IMI and the outcome of its therapy. Immunological components can thus be expected to play a pivotal role not only in the risk assessment and diagnosis, but also in the treatment of IMI. Cytokines could improve the reliability…

AdultMalemedicine.medical_specialtyTreatment responseAntifungal Agentshemato-oncological malignanciesAspergillosismucormycosis03 medical and health sciencesImmunocompromised HostImmune systemSDG 3 - Good Health and Well-beingInternal medicineNeoplasmsEpidemiologyimmunological statusmedicineHumansIntensive care medicine030304 developmental biologyAgedAged 80 and over0303 health sciencesHematology030306 microbiologybusiness.industryinvasive pulmonary aspergillosishematologyMucormycosisCancerReproducibility of ResultsGeneral MedicineMiddle Agedmedicine.diseaseInfectious Diseaseshemato-oncological malignancies; hematology; immunological status; invasive pulmonary aspergillosis; mucormycosisAcademicSubjects/SCI00960FemaleOriginal ArticleRisk assessmentbusinessAcademicSubjects/MED00010Invasive Fungal Infections
researchProduct

Hepatitis C virus viral kinetics during α-2a or α-2b pegylated interferon plus ribavirin therapy in liver transplant recipients with different immuno…

2012

Abstract Background Predictors of sustained virological response (SVR) to antiviral therapy post-liver transplantation (LT) for chronic hepatitis C are needed. In non-transplanted patients, viral kinetics can predict SVR. Objectives To determine the early viral kinetics in LT recipients with different immunosuppression (tacrolimus – Tac- vs. cyclosporine – CsA-) during treatment with peg-IFN + RBV. Study design Prospective pilot study in HCV-1b infected patients: (LT CsA n = 8; Tac n = 8; non-LT n = 4), treated with IFN α-2a vs. α-2b (180 μg or 1.5 μg/kg, respectively) once weekly plus weight-based RBV. Median CsA or Tac baseline trough levels were 141 and 7.70 ng/mL, respectively. HCV-RNA …

AdultMalemedicine.medical_specialtymedicine.medical_treatmentHepatitis C virusPilot ProjectsHepacivirusInterferon alpha-2Biologymedicine.disease_causeAntiviral AgentsGastroenterologyPolyethylene GlycolsImmunocompromised Hostchemistry.chemical_compoundPegylated interferonVirologyInternal medicineRibavirinmedicineHumansProspective StudiesAgedRibavirinInterferon-alphaImmunosuppressionHepatitis C ChronicMiddle AgedViral LoadViral kineticsRecombinant ProteinsTacrolimusLiver TransplantationTransplantationKineticsTreatment OutcomeInfectious DiseaseschemistryHost-Pathogen InteractionsImmunologyFemaleViral loadmedicine.drugJournal of Clinical Virology
researchProduct

Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients

2016

Background Invasive fungal infections are important causes of morbidity and mortality among critically ill patients. Early institution of antifungal therapy is pivotal for mortality reduction. Starting a targeted antifungal therapy after culture positivity and fungi identification requires a long time. Therefore, alternative strategies (globally defined as 'untargeted antifungal treatments') for antifungal therapy institution in patients without proven microbiological evidence of fungal infections have been discussed by international guidelines. This review was originally published in 2006 and updated in 2016. This updated review provides additional evidence for the clinician dealing with s…

Adultmedicine.medical_specialtyAntifungal drugMycoseintensive care medicinelaw.invention03 medical and health sciencesImmunocompromised Hostcritically ill patient0302 clinical medicineRandomized controlled triallawInternal medicineAmphotericin BmedicineHumansAntifungal AgentPharmacology (medical)030212 general & internal medicineMED/41 - ANESTESIOLOGIAIntensive care medicineFluconazoleFluconazole [therapeutic use]Randomized Controlled Trials as Topicbusiness.industryfungal infectionMicafungin030208 emergency & critical care medicinePublication biasMycoses [mortalityClinical trialCritical Illness [mortality]; Amphotericin B [therapeutic use]; Antifungal Agents [therapeutic use]; Fluconazole [therapeutic use]; Immunocompromised Host; Mycoses [mortality; prevention & control]; Randomized Controlled Trials as Topic; Adult; HumansAntifungal Agents [therapeutic use]prevention & control]Relative riskMeta-analysisAmphotericin B [therapeutic use]AnidulafunginCritical IllneCritical Illness [mortality]businessmedicine.drugHuman
researchProduct

Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease

2014

The treatment of inflammatory bowel disease (IBD) has been revolutionised over the past decade by the increasing use of immunomodulators, mainly azathioprine (AZA)/6-mercaptopurine (6-MP) and methotrexate (MTX), together with the advent of biological therapy. Immunomodulators are being used more often and earlier in the course of the disease.1 The introduction of biologic agents, especially inhibitors of the key proinflammatory cytokine, tumor necrosis factor alpha (TNF-α) initiated a new therapeutic era, whose use has grown continuously since their introduction in 1998.2 With such immunomodulation, the potential for opportunistic infection is a key safety concern for patients with IBD. Opp…

Adultmedicine.medical_specialtyEvidence-based practiceAdolescentOpportunistic infectionSettore MED/12 - GASTROENTEROLOGIAMEDLINEAzathioprineHIV InfectionsSettore MED/17 - MALATTIE INFETTIVEInflammatory bowel diseaseInflammatory bowel diseaseImmunocompromised HostYoung AdultRisk FactorsInfluenza HumanmedicineParasitic DiseasesHumansOpportunistic infectionsIntensive care medicineECCO guidelinesIrritable bowel syndromebusiness.industryPapillomavirus InfectionsGastroenterologyAge FactorsGeneral MedicineHerpesviridae InfectionsMiddle Agedmedicine.diseaseHepatitis BInflammatory Bowel DiseasesHepatitis CVaccinationMycosesInfectious disease (medical specialty)ImmunologyHuman medicinebusinessmedicine.drug
researchProduct

COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overvi…

2021

To date, four vaccines have been authorised for emergency use and under conditional approval by the European Medicines Agency to prevent COVID-19: Comirnaty, COVID-19 Vaccine Janssen, Spikevax (previously COVID-19 Vaccine Moderna) and Vaxzevria (previously COVID-19 Vaccine AstraZeneca). Although the benefit–risk profile of these vaccines was proven to be largely favourable in the general population, evidence in special cohorts initially excluded from the pivotal trials, such as pregnant and breastfeeding women, children/adolescents, immunocompromised people and persons with a history of allergy or previous SARS-CoV-2 infection, is still limited. In this narrative review, we critically overv…

AllergyIMPACTCOVID-19 VaccineBreastfeedingReview ArticleToxicologySettore MED/42 - Igiene Generale E ApplicataCLINICAL CHARACTERISTICSPregnancyPharmacology (medical)Pregnancy Complications InfectiousChildOUTCOMESeducation.field_of_studyCANCERVaccinationEuropeCORONAVIRUS DISEASE 2019 CLINICAL CHARACTERISTICS CANCER RECIPIENTS SEVERITY OUTCOMES IMPACT RATESBreast FeedingChild PreschoolPractice Guidelines as TopicFemale2019-nCoV Vaccine mRNA-1273HumanAdultmedicine.medical_specialtyCOVID-19 Vaccines2019-nCoV Vaccine mRNA-1273; Adolescent; Adult; BNT162 Vaccine; Breast Feeding; COVID-19; COVID-19 Vaccines; ChAdOx1 nCoV-19; Child; Child Preschool; Europe; Female; Humans; Infant; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications Infectious; SARS-CoV-2; Hypersensitivity; Immunocompromised HostAdolescentSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PopulationMEDLINECORONAVIRUS DISEASE 2019Immunocompromised HostChAdOx1 nCoV-19medicineHypersensitivityHumansRATESeducationBNT162 VaccinePharmacologyPregnancybusiness.industrySARS-CoV-2COVID-19Infantmedicine.diseaseVaccine efficacyRECIPIENTSSEVERITYFamily medicinePregnancy Complications Infectioubusiness
researchProduct

Nephrotoxicity in the setting of invasive fungal diseases

2008

Amphotericin B, a broad spectrum antifungal agent, is widely used despite significant adverse events including nephrotoxicity. Nephrotoxicity occurs frequently in patients receiving amphotericin B. Different definitions for nephrotoxicity are reviewed in the context of outcome in patients with invasive fungal diseases. In most publications, mortality was higher in patients experiencing nephrotoxicity and mean hospital length of stay was prolonged. As a consequence, the use of less nephrotoxic antifungal agents could improve treatment outcomes.

Antifungalmedicine.medical_specialtyAntifungal Agentsmedicine.drug_classTreatment outcomeLength of hospitalizationContext (language use)DermatologyNephrotoxicityImmunocompromised HostAmphotericin BAmphotericin BmedicineHumansIn patientIntensive care medicineAdverse effectbusiness.industryGeneral MedicineLength of StayTreatment OutcomeInfectious DiseasesMycosesKidney Diseasesbusinessmedicine.drugMycoses
researchProduct